NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Arch Therapeutics, Inc. (OTCQB:ARTH), developer of novel liquid, gel and solid hemostatic and wound care devices, is scheduled to provide a corporate update at this year’s New York City based Investor Summit on March 25th-26th.
During the current climate of concern, The Spring Investor Summit will now take place virtually, featuring over 500 registered executives and investors.
Investors will still be able to view all the company presentations directly in the conference event platform on the event days. 1:1’s will now be scheduled and conducted via phone lines with a dedicated PIN for each meeting.
You can view our company presentation via webcast here: https://www.webcaster4.com/Webcast/Page/2038/33626 on March 25th, 2020 at 8:25 a.m. EST.
About Arch Therapeutics, Inc.
Arch Therapeutics is developing innovative self-assembling barrier technologies to improve wound care outcomes, enhance the quality of patient care by healthcare personnel, and offer compelling options to healthcare institutions facing limited resources.
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
To register as a presenting company: please contact Cassandra Miller (cassandra@microcapconf.com)
To request complimentary investor registration: please visit our website at www.microcapconf.com
News Compliments of ACCESSWIRE
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Cassandra Miller at cassandra@microcapconf.com
SOURCE: Arch Therapeutics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/581272/Arch-Therapeutics-Inc-to-Present-at-the-New-York-City-based-Investor-Summit-on-March-25th-26th
Research highlights how nutrition tracking drives success for weight loss and health goals NEW YORK,…
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa., Dec. 26, 2024…
Slovenia, Croatia, Turkey, and Greece Drive EHR Adoption in the Balkans, Setting New Standards in…
Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…